<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Main heading</title></head><body><div><p style="line-height:12pt; margin:0pt"><span style="color:#7f7f7f; font-family:Arial; font-size:10pt">Submission to the </span><span style="color:#7f7f7f; font-family:Arial; font-size:10pt; font-weight:bold">Parliamentary Science and Technology Committee’s Inquiry into </span><span style="color:#7f7f7f; font-family:Arial; font-size:10pt; font-weight:bold">Blood, tissue and organ screening</span></p><p style="line-height:12pt; margin:0pt"><span style="color:#7f7f7f; font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><a name="_Toc377120463"></a><a name="_Toc377125974"></a><a name="_Toc377998470"></a><a name="_Toc150919533"></a><a name="_Toc180303268"></a><a name="_Toc351547627"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Public Health England</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> (BTO</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">03</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">)</span></a></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><span style="color:#98002e; font-family:Arial; font-size:24pt">Contents</span></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998469"><span style="color:#98002e; font-family:Arial; font-size:12pt">About Public Health England</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998471"><span style="color:#98002e; font-family:Arial; font-size:12pt">1. Executive summary</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998472"><span style="color:#98002e; font-family:Arial; font-size:12pt">2. Introduction</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998473"><span style="color:#98002e; font-family:Arial; font-size:12pt">3. Question 2</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998474"><span style="color:#98002e; font-family:Arial; font-size:12pt">4. Question 3</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998475"><span style="color:#98002e; font-family:Arial; font-size:12pt">Measures currently being taken to limit known risks</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998476"><span style="color:#98002e; font-family:Arial; font-size:12pt">Measures being taken to limit unknown risks</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998477"><span style="color:#98002e; font-family:Arial; font-size:12pt">Prion prevalence surveys of appendix tissue to further inform risk assessments</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998478"><span style="color:#98002e; font-family:Arial; font-size:12pt">Establishing the prevalence of abnormal prions in blood:</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998479"><span style="color:#98002e; font-family:Arial; font-size:12pt">5. References</span></a></p><p style="line-height:20pt; margin:0pt"><a href="#_Toc377998480"><span style="color:#98002e; font-family:Arial; font-size:12pt">6. Annexes</span></a></p><p style="line-height:20pt; margin:0pt"></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">              </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><br style="page-break-before:always; clear:both" /><a name="_Toc377998471"><span style="color:#98002e; font-family:Arial; font-size:24pt">1. </span><span style="color:#98002e; font-family:Arial; font-size:24pt">Executive summary</span></a></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">The following departments within Public Health England (PHE) contribute towards und</span><span style="color:#000000; font-family:Arial; font-size:12pt">erstanding of Creutzfeld-Jakob D</span><span style="color:#000000; font-family:Arial; font-size:12pt">isease</span><span style="color:#000000; font-family:Arial; font-size:12pt; font-weight:bold"> </span><span style="color:#000000; font-family:Arial; font-size:12pt">(CJD) epidemiology and contr</span><span style="color:#000000; font-family:Arial; font-size:12pt">ol in the UK</span><span style="color:#000000; font-family:Arial; font-size:12pt">: CJD section within the PHE Centre for Infectious Disease Surveil</span><span style="color:#000000; font-family:Arial; font-size:12pt">lance and Control (CIDSC); PHE microbiology s</span><span style="color:#000000; font-family:Arial; font-size:12pt">ervices (togethe</span><span style="color:#000000; font-family:Arial; font-size:12pt">r with CIDSC); PHE’s healthcare-</span><span style="color:#000000; font-family:Arial; font-size:12pt">associated infections and antimicrobial resistance teams; and various research areas. PHE also supports the Advisory Committee on Dangerous Pathogens (ACDP) subgroup on Transmissible Spongiform Encephalopathies (TSE). PHE also provides expert representation on the UK Blood Services Prion Working Group and The Advisory Committee on the Safety of Bl</span><span style="color:#000000; font-family:Arial; font-size:12pt">ood, Tissues and Organs (SaBTO)</span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">PHE will provide written evidence to questions 2 and 3 of the Science and Technology Select Committee’s Inquiry into the safety of blood, tissue and organ screening – with respect to abnorma</span><span style="color:#000000; font-family:Arial; font-size:12pt">l prions and variant CJD (vCJD)</span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">National expertise is brought together through expert groups to help interpret limited evidence and scientific uncertainty regarding vCJD, and identifying emerging evidence. National guidance on TSE infection prevention and control are maintained and updated regularly by such expert groups to re</span><span style="color:#000000; font-family:Arial; font-size:12pt">flect new evidence and policies</span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">Measures currently in place to limit kn</span><span style="color:#000000; font-family:Arial; font-size:12pt">own risks aim to prevent person-to-</span><span style="color:#000000; font-family:Arial; font-size:12pt">person spread of vCJD, both through blood and blood products and through surgical procedures. All people who are identified as “at increased risk” of vCJD are asked to help prevent any further possible transmission to other patients. PHE has had a role in identifying and informing individuals of their i</span><span style="color:#000000; font-family:Arial; font-size:12pt">ncreased risk of vCJD, and long-</span><span style="color:#000000; font-family:Arial; font-size:12pt">term public health follow-up is in place to detect any new diagnos</span><span style="color:#000000; font-family:Arial; font-size:12pt">es of vCJD in these individuals</span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">Measures to limit unknown risks through universal precautions concern both blood transfusion and surgery, and decontamination and sterilisation of surgical instruments.</span><span style="color:#000000; font-family:Arial; font-size:12pt"> </span><span style="color:#000000; font-family:Arial; font-size:12pt">After completion of a large anonymous survey of appendix tissues taken from persons after they had the opportunity for dietary exposure to BSE, PHE is now co-ordinating another major D</span><span style="color:#000000; font-family:Arial; font-size:12pt">epartment of Health</span><span style="color:#000000; font-family:Arial; font-size:12pt">-funded anonymous survey of appendix tissues taken at a time (pre-1980) when BSE was not in the food chain or from persons born after 1996 who will not have had dietary BSE exposure.</span><span style="color:#000000; font-family:Arial; font-size:12pt"> </span><span style="color:#000000; font-family:Arial; font-size:12pt">This second survey will help establish whether the 1 in 2000 prevalence of abnormal prion found in the earlier survey is limited to the population that had dietary BSE exposure</span></li></ul><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><br style="page-break-before:always; clear:both" /><a name="_Toc377998472"><span style="color:#98002e; font-family:Arial; font-size:24pt">2. Introduction</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566812"><span style="font-family:Arial; font-size:12pt">PHE</span><span style="font-family:Arial; font-size:12pt"> was established on 1 April 2013 to bring together public health specialists from more than 70 organisations into a single public health service.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Within the organisation several departments, which were formerly part of the Health Protection Agency (HPA), contribute expertise to increase understanding of the epidemiology of Creutzfeld-Jakob disease</span><span style="font-family:Arial; font-size:12pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:12pt">(C</span><span style="font-family:Arial; font-size:12pt">JD) and abnormal prio</span><span style="font-family:Arial; font-size:12pt">n disease and to prevent person-to-</span><span style="font-family:Arial; font-size:12pt">person spread.</span></a><a name="_Toc377566813"><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">These include:</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566814"><span style="color:#000000; font-family:Arial; font-size:12pt">t</span><span style="color:#000000; font-family:Arial; font-size:12pt">he CJD section in the </span><span style="color:#000000; font-family:Arial; font-size:12pt">CIDSC</span><span style="color:#000000; font-family:Arial; font-size:12pt">: supporting public health management of incidents where individuals may have been exposed to CJD through their healthcare and conducting long-term surveillance of persons at risk of variant-CJD (vCJD)</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566815"><span style="color:#000000; font-family:Arial; font-size:12pt">microbiology services (together with CIDSC): c</span><span style="color:#000000; font-family:Arial; font-size:12pt">o</span><span style="color:#000000; font-family:Arial; font-size:12pt">-</span><span style="color:#000000; font-family:Arial; font-size:12pt">ordination of and fieldwork for abnormal prion prevalence studies</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566816"><span style="color:#000000; font-family:Arial; font-size:12pt">healthcare b</span><span style="color:#000000; font-family:Arial; font-size:12pt">iotechnology, decontamination and T</span><span style="color:#000000; font-family:Arial; font-size:12pt">SE</span><span style="color:#000000; font-family:Arial; font-size:12pt"> r</span><span style="color:#000000; font-family:Arial; font-size:12pt">esearch: research on surgical instrument decontamination</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566817"><span style="color:#000000; font-family:Arial; font-size:12pt">healthcare-</span><span style="color:#000000; font-family:Arial; font-size:12pt">associated infections and antimicrobial resistance: maintain the national expert Rapid Review Panel </span><span style="color:#000000; font-family:Arial; font-size:12pt">(RRP) </span><span style="color:#000000; font-family:Arial; font-size:12pt">for assessment of new and novel equipment, materials, and other products or protocols that may be of value to the NHS in improving hospital infection control and reducing hospital acquired infections</span></a></li></ul><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566818"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">In addition, </span><span style="font-family:Arial; font-size:12pt">the HPA provided medical and scientific secretariat support for the CJD Incidents Panel between 2003 and its dissolution in 2013.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">PHE continues to support the Advisory Committee on Dangerous Pathogens (ACDP) TSE subgroup</span><span style="font-family:Arial; font-size:12pt">,</span><span style="font-family:Arial; font-size:12pt"> which provides expert advice on the risk assessment and risk management of potential person</span><span style="font-family:Arial; font-size:12pt">-to-</span><span style="font-family:Arial; font-size:12pt">pers</span><span style="font-family:Arial; font-size:12pt">on spread of CJD through healthcare. </span><span style="font-family:Arial; font-size:12pt">PHE also has expert representation on the UK Blood services prion working group and The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO), which has developed and published guidance relating to the prevention of CJD transmission, among other infections.</span><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566819"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">This submission focuse</span><span style="font-family:Arial; font-size:12pt">s on aspects of risks of person-to-</span><span style="font-family:Arial; font-size:12pt">person spread of vCJD and abnormal prions, and provides written evidence in respect of questions 2 and 3 of the Parliamentary Science and Technology Select Committee:</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566820"><span style="color:#000000; font-family:Arial; font-size:12pt">Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566821"><span style="color:#000000; font-family:Arial; font-size:12pt">Has the threat of ongoing transmission of vCJD through the blood and blood product supply been adequately mitigated?</span></a></li></ul><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><br style="page-break-before:always; clear:both" /><a name="_Toc377998473"><span style="color:#98002e; font-family:Arial; font-size:24pt; font-weight:normal">3. </span><span style="color:#98002e; font-family:Arial; font-size:24pt; font-weight:normal">Question 2</span></a><span style="color:#98002e; font-family:Arial; font-size:24pt; font-weight:normal"> </span></p><p style="line-height:18pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566823"><span style="font-family:Arial; font-size:14pt; font-weight:bold">Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566824"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">The expert groups, for which PHE provides or has provided scientific secretariat support and/or expert contribution, bring together national expertise and experience to help interpret limited evidence and scientific uncertainty regarding vCJD.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">They commission, consider and interpret risk assessments of the potential for vCJD transmission through blood components and other aspects of healthcare. New evidence is regularly reviewed in order to formulate strategies and recommendations for risk management and risk reduction.</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566825"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">The number, format and specific functions of these expert groups have changed over the years.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The ACDP TSE group, and its predecessors (the ACDP TSE Risk Management group and the TSE Working Group) own and oversee the national guidance on TSE infection prevention and control, and these documents are maintained and updated regularly to reflect new evidence and policies (such as decontamination policies) as they arise.</span><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><a name="_Toc377998474"><span style="color:#98002e; font-family:Arial; font-size:24pt">4. </span><span style="color:#98002e; font-family:Arial; font-size:24pt">Question 3</span></a></p><p style="line-height:18pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566827"><span style="font-family:Arial; font-size:14pt; font-weight:bold">Has the threat of ongoing transmission of vCJD through the blood and blood product supply been adequately mitigated?</span></a></p><p style="line-height:18pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:14pt; font-weight:bold">&#xa0;</span></p><p style="line-height:18pt; margin:0pt 0pt 16pt"><a name="_Toc377998475"><span style="color:#98002e; font-family:Arial; font-size:14pt">Measures currently being taken to limit known risks</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566829"><span style="font-family:Arial; font-size:12pt">A number of safety measures ar</span><span style="font-family:Arial; font-size:12pt">e in place to prevent person-to-</span><span style="font-family:Arial; font-size:12pt">person spread of vCJD, both through blood and blood products and through surgical procedures.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">These measures concern transmission risks both from patients who have been diagnosed with clinical vCJD, and those who are healthy but who have been exposed to an increased risk of vCJD through their healthcare.</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566830"><span style="font-family:Arial; font-size:12pt">This second group of patients may never develop the disease but because there is no in-life test to detect asymptomatic infection, there is a potential for transmission of infection to occur before symptoms become apparent during a possibly prolonged incubation period to vCJD.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Therefore, a precautionary approach is taken with the</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">formulation of infection prevention and control advice, given the many uncertainties in this area, and the serious consequences of hidden transmission.</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566831"><span style="font-family:Arial; font-size:12pt; text-decoration:underline">Identification and follow-up of individuals at increased risk of vCJD</span></a><span style="font-family:Arial; font-size:12pt; text-decoration:underline"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566832"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">There are around 3,500 individuals</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:Arial; font-size:12pt"> in the UK who have been informed that they have an increased risk of vCJD (see Annex A).</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">This figure comprises a mix of:</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566833"><span style="color:#000000; font-family:Arial; font-size:12pt">individuals with a known link to a clinical case of vCJD (through donation or receipt of blood or blood products, receipt of certain pooled plasma products or following surgical exposure)</span></a><span style="color:#000000; font-family:Arial; font-size:12pt"> </span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566834"><span style="color:#000000; font-family:Arial; font-size:12pt">groups of individuals, not linked directly to a clinical case but who, on the basis of a risk assessment, are defined as likely to have been exposed to a high enough risk of exposure through their treatment with blood or plasma products to inform them about this risk, where possible, and to recommend that public health precautions concerning blood, tissues, organs and surgery are followed</span></a></li></ul><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566835"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">All people who are “at increased risk” of vCJD are as</span><span style="font-family:Arial; font-size:12pt">ked to help prevent any further </span><span style="font-family:Arial; font-size:12pt">possible transmission to other patients by following the advice beneath, published by the ACDP TSE group (see box).</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr style="height:288.95pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:488.45pt"><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566836"><span style="font-family:Arial; font-size:12pt; font-weight:bold">Box: Public health advice on how to stop CJD spreading to other people</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566837"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">This advice is for people who have been identified as being at increased risk of CJD. To reduce the risk of spreading CJD to other people please follow this advice:</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566838"><span style="color:#000000; font-family:Arial; font-size:12pt">d</span><span style="color:#000000; font-family:Arial; font-size:12pt">on’t donate blood. No-one who is “at increased risk” of CJD/vCJD, or who has received blood donated in the U</span><span style="color:#000000; font-family:Arial; font-size:12pt">K</span><span style="color:#000000; font-family:Arial; font-size:12pt"> since 1980, should donate blood</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566839"><span style="color:#000000; font-family:Arial; font-size:12pt">d</span><span style="color:#000000; font-family:Arial; font-size:12pt">on’t donate organs or tissues, including bone marrow, sperm, eggs or breast milk</span></a></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566840"><span style="color:#000000; font-family:Arial; font-size:12pt">i</span><span style="color:#000000; font-family:Arial; font-size:12pt">f you are going to have any medical, dental or surgical procedures, tell whoever is treating you beforehand so they can make special arrangements for the instruments used to treat you if you need certain types of surgery or investigation</span></a><span style="color:#000000; font-family:Arial; font-size:12pt"> </span></li><li style="color:#98002e; font-family:Symbol; font-size:12pt; line-height:16pt; margin:0pt 39.7pt 0pt 10.52pt; padding-left:7.33pt; text-indent:0pt"><a name="_Toc377566841"><span style="color:#000000; font-family:Arial; font-size:12pt">y</span><span style="color:#000000; font-family:Arial; font-size:12pt">ou are advised to tell your family about your increased risk. Your family can tell the people who are treating you about your increased risk of CJD/vCJD if you need medical or surgical procedures in the future and you are unable to tell them yourself</span></a></li></ul></td></tr></table><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566842"><span style="font-family:Arial; font-size:12pt">Through its past work with the CJD Incidents Panel, PHE has had a role in identifying and informing individuals of their increased risk of vCJD.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">This was done in collaboration with the National Blood service (now NHS BT) and the UK Haemophilia Centre Doctors organisation.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Long</span><span style="font-family:Arial; font-size:12pt">-</span><span style="font-family:Arial; font-size:12pt">term public health follow-up is in place to detect any new diagnoses of vCJD in these individuals.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">This systematic co</span><span style="font-family:Arial; font-size:12pt">-</span><span style="font-family:Arial; font-size:12pt">ordinated follow-up was put in place after the identification of three transfusion-associated cases of vCJD and the detection, post mortem, of prion protein deposition in tissues from two individuals (one with a history of blood transfusion, and the other of plasma product treatment) neither of whom had symptoms of </span><span style="font-family:Arial; font-size:12pt">v</span><span style="font-family:Arial; font-size:12pt">CJD.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Any further detection of iatrogenic transmission of vCJD via blood, tissues, organs or surgery, would be immediately notified and would lead to a re-assessment of current guidance and precautions.</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:18pt; margin:0pt 0pt 16pt"><a name="_Toc377998476"><span style="color:#98002e; font-family:Arial; font-size:14pt">Measures being taken to limit unknown risks</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566844"><span style="font-family:Arial; font-size:12pt; text-decoration:underline">Related to blood transfusion and surgery</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566845"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">The public health actions described above apply to individuals who have been identified and informed about their vCJD risk status or transfusion history.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">In addition, there are a number of universal precautions in place to protect public health from the unknown but potential risk of undiagnosed vCJD infection within the general population.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">These include donor deferral of any person who has received a UK blood transfusion since 1980 and universal leucocyte depletion of blood used for transfusion [1].</span><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 53.8pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">In addition, public health guidelines from NICE protect the general population from surgical risk by recommending, among other things, the use of segregated sets of neurosurgical instruments on patients born after 1996, who are presumed not to have been exposed to the dietary risks of vCJD [2]. This is to prevent accidental transmission following neurosurgery on an individual in the population exposed to dietary BSE who could theoretically be carrying an undiagnosed vCJD infection which could be passed on.</span><a name="_Toc377566846"></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt; text-decoration:underline">Related to decontamination and sterilisation of surgical instruments</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566847"><span style="font-family:Arial; font-size:12pt">A further general approach to reducing the risk from vCJD to the general population is the improvement of decontamination techniques to remove prion protein from surgical instruments.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">PHE hosts the national expert </span><span style="font-family:Arial; font-size:12pt">RRP, </span><span style="font-family:Arial; font-size:12pt">which provides a prompt assessment of new and novel equipment, materials, and other products or protocols that may be of value to the NHS in improving hospital infection control and reducing hospital acquired infections.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">For a full description of the RRP, its role, remit and procedures, see A</span><span style="font-family:Arial; font-size:12pt">nnex</span><span style="font-family:Arial; font-size:12pt"> B.</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566848"><span style="font-family:Arial; font-size:12pt">The RRP reviewed the applicatio</span><span style="font-family:Arial; font-size:12pt">n from DuPont for the product “</span><span style="font-family:Arial; font-size:12pt">Rel</span><span style="font-family:Arial; font-size:12pt">yOn Prion Inactivator” </span><span style="font-family:Arial; font-size:12pt">(RelyOn-PI) on two occasions.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">RelyOn-PI is DuPont’s patented solution claimed to “very substantially reduce the risk of transmission of prions bound to surgical instruments”.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The modus operandi of RelyOn-PI can be found in A</span><span style="font-family:Arial; font-size:12pt">nnex</span><span style="font-family:Arial; font-size:12pt"> C, Section 2.5.</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566849"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">The first application concerning RelyOn-PI was reviewed by the RRP in June 2007, awarded a level 3 recommendation (“A potentially useful new concept but insufficiently validated; more research and development is required before it is ready for evaluation in practice”), and the applicants provided with detailed feedback concerning gaps and weaknesses within the evidence base.</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">At a second review in December 2008, the RRP awarded a level 2 recommendation (“Basic research and development has been completed and the product may have potential value; in use evaluations/trials are now needed in an NHS clinical setting” – see Annex D).</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">This second commentary to the company outlined concerns with the product which DuPont had yet to address.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">These were communicated to DuPont after both applications in 2007 and 2008 (Annex E for the full 2008 commentary).</span><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566850"><span style="font-family:Arial; font-size:12pt">Specifically in the RRP feedback followi</span><span style="font-family:Arial; font-size:12pt">ng the 2008 review, DuPont was “</span><span style="font-family:Arial; font-size:12pt">again advised to engage with the Department of Health’s Engineering &amp; Science Advisory Committee for the decontamination of surgical instruments including Prion Removal regarding compatibility with existing procedures and how the</span><span style="font-family:Arial; font-size:12pt"> product will fit into practice”</span><span style="font-family:Arial; font-size:12pt">.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The RRP secretariat is aware that in April 2010 DuPont approached Infection Control Product </span><span style="font-family:Arial; font-size:12pt">Specialist Dr Beryl Oppenheim (consultant m</span><span style="font-family:Arial; font-size:12pt">icrobiologist, City Hospital Birmingham) who convened an expert group to work with and advise DuPont.</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:18pt; margin:0pt 0pt 16pt"><a name="_Toc377998477"><span style="color:#98002e; font-family:Arial; font-size:14pt">Prion prevalence surveys of appendix tissue to further inform risk assessments</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566852"><span style="font-family:Arial; font-size:12pt">PHE undertakes anonymised population prevalence surveys to increase understanding of the epidemiology and scale of background undiagnosed abnormal prion infections.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The results have helped to inform public health guidance.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The most recent survey, which tested tissue archived following routine surgery, demonstrated a 1:2000 prevalence of abnormal prion deposition in appendices of individuals born between 1941 and 1985 [3].</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Although it is not known whether this finding equates to infectivity in tissues or in the blood of those with prion deposition, on a precautionary basis it supports the maintenance of the current public health safety measures, until a practical and reliable screening test for asymptomatic infection becomes available.</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566853"><span style="font-family:Arial; font-size:12pt">A further anonymised appendix study in UK populations assumed </span><span style="font-family:Arial; font-size:12pt; text-decoration:underline">non-exposed</span><span style="font-family:Arial; font-size:12pt"> to dietary BSE is under</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">way (again PHE co-ordinated and in collaboration with a range of partners).</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Appendices removed from patients (of any age) prior to 1979 and from those born after 1996, when full safety measures to protect the food chain were in place are being tested.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">This will provide a comparison population result to help interpret the findings from the earlier survey.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The latest survey will conclude in 2015.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">PHE will present any interim findings from the appendix study on an ongoing basis to the relevant expert groups.</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:18pt; margin:0pt 0pt 16pt"><a name="_Toc377998478"><span style="color:#98002e; font-family:Arial; font-size:14pt">Establishing the prevalence of abnormal prions in blood:</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566855"><span style="font-family:Arial; font-size:12pt">If the current appendix study demonstrates that the deposition of abnormal prion protein is confined to the population that was exposed to the BSE epidemic, the case for an anonymised population blood prevalence survey would be further increased – although there are a number of associated issues which would have to be considered very carefully.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">If there is no difference the priorities for further research and the implications for current public health protection measures would have to be re-evaluated.</span></a><span style="font-family:Arial; font-size:12pt"> </span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566856"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Since 2006/7 the advice of HPA (now PHE) experts and others has been that it is a priority to establish the prevalence of TSE reactivity in UK blood donations.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Five years ago a protocol for an unlinked anonymous survey of 50,000 UK blood donors was developed jointly by the HPA and NHS-BT, and Research Ethics Committee approval was obtained,</span><span style="font-family:Arial; font-size:12pt"> in anticipation of a suitable “</span><span style="font-family:Arial; font-size:12pt">med</span><span style="font-family:Arial; font-size:12pt">ium to high throughput”</span><span style="font-family:Arial; font-size:12pt"> blood test becoming available, the results of which could be usefully interpreted [4].</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Although this protocol needs updating to take account of new developments, it remains an important expression of HPA/PHE thinking with respect to a blood survey of abnormal prion prevalence.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">All technical experts who have considered the matter are aware that the blood test requirements for an unlinked anonymous prevalence survey need not be as rigorous as a blood test for strengthening blood safety (i.e. screening and excluding blood donations).</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566857"><span style="font-family:Arial; font-size:12pt">The </span><span style="font-family:Arial; font-size:12pt">results of the second appendix survey [3] (in the absence of furth</span><span style="font-family:Arial; font-size:12pt">er appendix prevalence results –</span><span style="font-family:Arial; font-size:12pt"> paras 18-19) strengthens arguments for </span><span style="font-family:Arial; font-size:12pt">establishing the prevalence of “prionaemia”</span><span style="font-family:Arial; font-size:12pt"> in UK blood.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The assessment by the current relevant national UK advisory committee</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">(The ACDP TSE RA Sub-Group) of the second appendix survey results (</span></a><a href="http://transparency.dh.gov.uk/2012/08/13/tse-risk-assessment-july-2012/"><span style="font-family:Arial; font-size:12pt">http://transparency.dh.gov.uk/2012/08/13/tse-risk-assessment-july-2012/</span></a><span style="font-family:Arial; font-size:12pt">) was that “</span><span style="font-family:Arial; font-size:12pt">gaining further information on prevalence of infection also remains a key area, especially through the investigation of tissues from groups unexposed to BSE and of the feasibility of surveying the prevalence of </span><span style="font-family:Arial; font-size:12pt">abnormal prion protein in blood”</span><span style="font-family:Arial; font-size:12pt">.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The full results of the second appendix surve</span><span style="font-family:Arial; font-size:12pt">y included the conclusion that “</span><span style="font-family:Arial; font-size:12pt">it would be prudent to measure the prevalence of abnormal PrP in human blood. As soon as a satisfactory human blood screening test becomes available in a scalable format, such an unlinked anonym</span><span style="font-family:Arial; font-size:12pt">ous survey should be undertaken”</span><span style="font-family:Arial; font-size:12pt">. [3]</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><a name="_Toc377566858"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Since 2011, HPA/PHE experts have had exploratory meetings to develop ideas as to how a blood prevalence survey could be progressed.</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">Issues discussed include a) uncertainty about the specificity of available blood tests (since addressed through additional work)</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">b) the need fo</span><span style="font-family:Arial; font-size:12pt">r at least a “medium-throughput”</span><span style="font-family:Arial; font-size:12pt"> format test for a survey on the scale required, and c) challenges in confir</span><span style="font-family:Arial; font-size:12pt">ming and interpreting “positive”</span><span style="font-family:Arial; font-size:12pt"> results. On this latter point, however, there is appreciation that further investigation of reactive specimens would be facilitated by i) the likely availability o</span><span style="font-family:Arial; font-size:12pt">f surplus suitable specimens (ie</span><span style="font-family:Arial; font-size:12pt"> the remainder </span><span style="font-family:Arial; font-size:12pt">of any reactive blood specimen –</span><span style="font-family:Arial; font-size:12pt"> unlike the situation with appendices), ii) the field of possible confirmatory tests has been progressing steadily, and iii)</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">the unlinked-anonymous design would avoid the difficulty of having to convey uncertain results directly to subjects from whom blood specimens are obtained (as is the case for the positive appendix specimens).</span><span style="font-family:Arial; font-size:12pt"> </span><span style="font-family:Arial; font-size:12pt">The critical aspect was identified as having the primary test in a format that could be used relatively efficiently and consistently when testing approximately 50,000 specimens.</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><a name="_Toc377998479"><span style="color:#98002e; font-family:Arial; font-size:24pt">5. </span><span style="color:#98002e; font-family:Arial; font-size:24pt">References</span></a></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Arial; font-size:12pt; line-height:16pt; margin:0pt 0pt 0pt 15.01pt; padding-left:6.29pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">Joint UKBTS / HPA Professional Advisory Committee Position Statement, November 2012.</span><span style="color:#000000; font-family:Arial; font-size:12pt"> </span><a href="http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=794"><span style="color:#000000; font-family:Arial; font-size:12pt">http://www.transfusionguidelines.org.uk/index.aspx?Publication=DL&amp;Section=12&amp;pageid=794</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">.</span></li></ol><p style="line-height:16pt; margin:0pt 0pt 0pt 21.3pt; text-indent:-21.3pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Arial; font-size:12pt; line-height:16pt; margin:0pt 0pt 0pt 15.01pt; padding-left:6.29pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">NICE 2006. Patient safety and reduction of risk of tr</span><span style="color:#000000; font-family:Arial; font-size:12pt">ansmission of Creutzfeldt-Jakob </span><span style="color:#000000; font-family:Arial; font-size:12pt">disease (CJD) via interventional procedures (IPG196)</span><span style="color:#000000; font-family:Arial; font-size:12pt">.</span></li></ol><p style="line-height:16pt; margin:0pt 0pt 0pt 21.3pt; text-indent:-21.3pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Arial; font-size:12pt; line-height:16pt; margin:0pt 0pt 0pt 15.01pt; padding-left:6.29pt; text-indent:0pt"><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Gill%20ON%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Gill ON</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Spencer%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Spencer Y</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Richard-Loendt%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Richard-Loendt A</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kelly%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Kelly C</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Dabaghian%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Dabaghian R</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Boyes%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Boyes L</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Linehan%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Linehan J</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Simmons%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Simmons M</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Webb%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Webb P</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bellerby%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Bellerby P</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Andrews%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Andrews N</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hilton%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Hilton DA</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Ironside%20JW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Ironside JW</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Beck%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Beck J</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Poulter%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Poulter M</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mead%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Mead S</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">, </span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Brandner%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24129059"><span style="color:#000000; font-family:Arial; font-size:12pt">Brandner S</span></a><span style="color:#000000; font-family:Arial; font-size:12pt">. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=gill+cjd+2013"><span style="color:#000000; font-family:Arial; font-size:12pt">BMJ.</span></a><span style="color:#000000; font-family:Arial; font-size:12pt"> 2013 Oct 15;347</span><span style="color:#000000; font-family:Arial; font-size:12pt">.</span></li></ol><p style="line-height:16pt; margin:0pt 0pt 0pt 21.3pt; text-indent:-21.3pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#98002e; font-family:Arial; font-size:12pt; line-height:16pt; margin:0pt 0pt 0pt 15.01pt; padding-left:6.29pt; text-indent:0pt"><span style="color:#000000; font-family:Arial; font-size:12pt">Eglin R, Soldan S, Newham J, Clewley J, Andrews N, Minor P, Gill N.</span><span style="color:#000000; font-family:Arial; font-size:12pt"> </span><span style="color:#000000; font-family:Arial; font-size:12pt">Proposal for a study of the prevalence in the British population of abnormal prions in blood. HPA Annual Conference, Warwick 2007.</span></li></ol><p style="line-height:18pt; margin:0pt 0pt 18pt 36pt"><span style="font-family:Arial; font-size:13pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 0pt"><br style="page-break-before:always; clear:both" /><a name="_Toc377998480"><span style="color:#98002e; font-family:Arial; font-size:24pt">6. </span><span style="color:#98002e; font-family:Arial; font-size:24pt">Annexes</span></a></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Annex A: PHE Health Protection Report. Vol 7 No 33 16 Aug 2013 – CJD Biannual report pages 9-11</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Annex B: Rapid Review Panel role and remit of review and procedure</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Annex C: RRP application form RelyOn prion inactivator – </span><span style="font-family:Arial; font-size:12pt; font-weight:bold">Commercial – In confidence</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Annex D: RRP recommendation 2 – Relyon prion inactivator</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="line-height:16pt; margin:0pt 39.7pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">Annex E: Comment to DuPont RelyOn PI – </span><span style="font-family:Arial; font-size:12pt; font-weight:bold">Commercial – In confidence</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="line-height:33pt; margin:0pt 39.7pt 24pt 36pt"><span style="color:#98002e; font-family:Arial; font-size:24pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:12pt">10</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="line-height:12pt; margin:0pt 53.8pt 0pt 0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="color:#98002e; font-family:Arial; font-size:9pt"> </span><span style="color:#98002e; font-family:Arial; font-size:9pt">This </span><span style="color:#98002e; font-family:Arial; font-size:9pt">figure</span><span style="color:#98002e; font-family:Arial; font-size:9pt"> excludes around 1,500 who are at increased risk of CJD be</span><span style="color:#98002e; font-family:Arial; font-size:9pt">cause they have received human growth h</span><span style="color:#98002e; font-family:Arial; font-size:9pt">ormone, as the iatrogenic risk through this product is not of variant CJD.</span></p></body></html>